Japan
Dioseve is a burgeoning player in the Biotechnology and Health Care industries, poised to transform infertility treatments. Founded in 2021, the company is headquartered in Japan and is devoted to the pioneering mission of "creating human eggs from iPS cells." Through its cutting-edge technology that develops fertilizable eggs from iPS and ES cells, Dioseve aims to offer revolutionary solutions for couples facing infertility.
Recently, the company secured a substantial ¥1.00 billion in Series A funding on 27 June 2024. This investment round saw participation from notable venture capital firms, including ANRI, Archetype Ventures, DG Daiwa Ventures, Future Venture Capital, Spiral Capital, and QR Investment. This financial backing underscores confidence in Dioseve's innovative approach and its potential impact on the global infertility treatment market. As Dioseve continues to advance its research and development efforts, it stands at the forefront of a significant medical breakthrough.
